Aptose Biosciences (APTO) Competitors $0.24 -0.03 (-10.95%) (As of 11/21/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends APTO vs. IKT, INAB, AIM, PMCB, NKGN, TSBX, SNTI, EVAX, COEP, and BCLIShould you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include Inhibikase Therapeutics (IKT), IN8bio (INAB), AIM ImmunoTech (AIM), PharmaCyte Biotech (PMCB), NKGen Biotech (NKGN), Turnstone Biologics (TSBX), Senti Biosciences (SNTI), Evaxion Biotech A/S (EVAX), Coeptis Therapeutics (COEP), and Brainstorm Cell Therapeutics (BCLI). These companies are all part of the "biological products, except diagnostic" industry. Aptose Biosciences vs. Inhibikase Therapeutics IN8bio AIM ImmunoTech PharmaCyte Biotech NKGen Biotech Turnstone Biologics Senti Biosciences Evaxion Biotech A/S Coeptis Therapeutics Brainstorm Cell Therapeutics Aptose Biosciences (NASDAQ:APTO) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, community ranking, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership. Is APTO or IKT more profitable? Inhibikase Therapeutics' return on equity of -350.63% beat Aptose Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Aptose BiosciencesN/A -5,683.22% -300.44% Inhibikase Therapeutics N/A -350.63%-201.82% Which has better earnings & valuation, APTO or IKT? Inhibikase Therapeutics has higher revenue and earnings than Aptose Biosciences. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptose BiosciencesN/AN/A-$51.21M-$2.97-0.08Inhibikase Therapeutics$260K57.67-$19.03M-$2.67-0.75 Do insiders & institutionals believe in APTO or IKT? 26.6% of Aptose Biosciences shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 3.9% of Aptose Biosciences shares are held by insiders. Comparatively, 14.7% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, APTO or IKT? Aptose Biosciences has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Does the media prefer APTO or IKT? In the previous week, Aptose Biosciences had 2 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 6 mentions for Aptose Biosciences and 4 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.88 beat Aptose Biosciences' score of 0.01 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptose Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Inhibikase Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend APTO or IKT? Aptose Biosciences presently has a consensus price target of $4.33, suggesting a potential upside of 1,675.96%. Inhibikase Therapeutics has a consensus price target of $6.50, suggesting a potential upside of 223.38%. Given Aptose Biosciences' higher probable upside, equities analysts clearly believe Aptose Biosciences is more favorable than Inhibikase Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptose Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Inhibikase Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor APTO or IKT? Aptose Biosciences received 369 more outperform votes than Inhibikase Therapeutics when rated by MarketBeat users. However, 90.00% of users gave Inhibikase Therapeutics an outperform vote while only 63.32% of users gave Aptose Biosciences an outperform vote. CompanyUnderperformOutperformAptose BiosciencesOutperform Votes37863.32% Underperform Votes21936.68% Inhibikase TherapeuticsOutperform Votes990.00% Underperform Votes110.00% SummaryInhibikase Therapeutics beats Aptose Biosciences on 8 of the 15 factors compared between the two stocks. Ad Behind the Markets📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Take these 4 steps to protect your retirement here >>> Get Aptose Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APTO vs. The Competition Export to ExcelMetricAptose BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.51M$2.93B$5.07B$8.89BDividend YieldN/A1.91%4.99%4.07%P/E Ratio-0.0915.0083.5712.93Price / SalesN/A280.711,220.3088.33Price / CashN/A168.0739.4636.25Price / Book-0.554.696.936.25Net Income-$51.21M-$41.63M$119.12M$225.93M7 Day Performance-28.32%-4.73%-1.83%-1.32%1 Month Performance-29.78%-6.53%-3.64%0.60%1 Year Performance-89.29%25.63%31.64%26.23% Aptose Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APTOAptose Biosciences2.22 of 5 stars$0.24-10.9%$4.33+1,676.0%-90.0%$4.42MN/A-0.0831Analyst ForecastNews CoverageGap UpHigh Trading VolumeIKTInhibikase Therapeutics2.7466 of 5 stars$2.01+1.5%$6.50+223.4%+130.1%$15.00M$260,000.00-0.758INABIN8bio3.2176 of 5 stars$0.32flat$7.75+2,321.9%-62.8%$14.97MN/A-0.4320AIMAIM ImmunoTech1.7806 of 5 stars$0.21+5.0%$3.00+1,317.1%-52.0%$13.49M$200,000.00-0.4520News CoverageHigh Trading VolumePMCBPharmaCyte Biotech0.651 of 5 stars$1.75+1.7%N/A-21.1%$13.44MN/A2.732NKGNNKGen BiotechN/A$0.34+6.3%N/A-89.1%$11.94M$80,000.00-0.06N/AGap UpHigh Trading VolumeTSBXTurnstone Biologics3.2023 of 5 stars$0.47+2.1%$2.13+352.6%-84.8%$10.86M$19.31M-0.1482SNTISenti Biosciences1.0759 of 5 stars$2.12flatN/A-42.1%$9.73M$2.56M-0.144News CoverageEVAXEvaxion Biotech A/S3.1433 of 5 stars$1.37-2.1%$11.00+702.9%-81.7%$8.04M$70,000.000.0049COEPCoeptis TherapeuticsN/A$0.19flatN/A-83.3%$7.81M$80,000.00-0.652BCLIBrainstorm Cell Therapeutics4.4621 of 5 stars$1.24-1.6%$30.00+2,319.4%-53.4%$7.07MN/A-0.2640Analyst UpgradePositive News Related Companies and Tools Related Companies Inhibikase Therapeutics Competitors IN8bio Competitors AIM ImmunoTech Competitors PharmaCyte Biotech Competitors NKGen Biotech Competitors Turnstone Biologics Competitors Senti Biosciences Competitors Evaxion Biotech A/S Competitors Coeptis Therapeutics Competitors Brainstorm Cell Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:APTO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
